Expert Perspectives on Recent Advances in Alzheimer’s Disease

Four Alzheimer’s disease expert discuss our current understanding of Alzheimer’s disease pathology and the presence of amyloid and tau pathologies in patients.

Drs Atri and Cohen discuss biomarkers for Alzheimer’s disease and the challenges in their use in routine practice.

Drs McDade and Sabbagh discuss heterogeneity in Alzheimer’s disease and structural polymorphism and genetic mosaicism seen in patients.

Dr Atri shares his excitement about ongoing research and the use of biomarkers and imaging for management Alzheimer’s disease.

Dr. Atri discusses his approach to diagnosis and Dr. McDade updates on the use of tau-PET for diagnosis of Alzheimer’s disease.

Dr Cohen emphasizes the importance of engagement of primary care physicians in identification of Alzheimer’s disease symptoms and pathology.

Drs McDade and Cohen discuss ATN (amyloid, tau, neurodegeneration) classification and its use in clinical practice to manage Alzheimer’s disease.

Dr. Cohen shares factors that may have contributed to the high failure rate of Alzheimer’s disease clinical trials thus far.

Dr Atri discusses considerations and suggestions for caring for patients with Alzheimer’s disease.

Dr Cohen shares current treatment options for Alzheimer’s disease and how she manages these patients in her practice.

Dr Atri emphasizes importance of managing neuropsychiatric symptoms in patients with Alzheimer’s disease and drugs under development.

Drs McDade, Atri, Cohen, and Sabbagh discuss candidates drugs and various mechanisms of actions that are currently under evaluation for Alzheimer’s disease.

Dr Atri discusses aducanumab, first FDA approved anti-amyloid-beta antibody for treatment of Alzheimer’s disease.

Dr Atri comments on observation of amyloid related imaging abnormalities (ARIA) seen with many Alzheimer’s disease treatments and shares his thoughts on management of ARIA.

Drs Cohen, Atri, and Sabbagh share data on lecanemab, an anti-amyloid beta antibody, that was presented at CTAD 2022.

Drs McDade and Atri discuss differences and similarities between other ongoing anti-amyloid antibody trials in Alzheimer’s disease.

Expert neurologists share information on drugs with different mechanisms of actions that are being evaluated in clinical trials for Alzheimer’s disease.

Dr Eric McDade shares information on different types of prevention trials to manage Alzheimer’s disease.

Drs Atri, Cohen, Sabbagh and McDade share their enthusiasm and optimism about the future outlook for Alzheimer’s disease.